Is Vitamin D3 a Worthy Supplement Protecting against Secondary Infections in Dogs with Atopic Dermatitis?
- PMID: 36678493
- PMCID: PMC9860574
- DOI: 10.3390/pathogens12010145
Is Vitamin D3 a Worthy Supplement Protecting against Secondary Infections in Dogs with Atopic Dermatitis?
Abstract
Canine atopic dermatitis (CAD) is a common, chronic, inflammatory skin disease in dogs worldwide. This disease often predisposes for secondary organisms overgrowth and skin infections with pathogens, such as Staphylococcus pseudintermedius and Malassezia pachydermatis. Unfortunately, the causes of this disease in both humans and animals are not fully understood; therefore, the only possible option is a lifelong, symptomatic treatment. The management of CAD is mainly based on limiting contact with allergens and antipruritic therapy, most often with glucocorticoids and antihistamines. A serious problem in this situation is the fact, that long-term administration of glucocorticoids leads to side effects like polyuria, alopecia, increased susceptibility to infection, muscle atrophy, and many others. For this reason, great emphasis is placed on the development of replacement and supportive therapies. It is a well-documented fact that reduced concentrations of serum vitamin D3 contribute to the severity of atopic dermatitis symptoms in humans. Moreover, unlike the most commonly used therapeutic methods, of which the main goal is to ameliorate inflammation and pruritus, namely the symptoms of AD, vitamin D3 supplementation affects some underlying factors of this disease. Therefore, in this review, we summarize the current state of knowledge regarding the role of vitamin D3 in CAD, its protective effect against secondary bacterial and fungal infections, and the potential of its supplementation in dogs.
Keywords: Malassezia pachydermatis; Staphylococcus pseudintermedius; antimicrobial peptides; canine atopic dermatitis; vitamin D3.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Antibody levels to Malassezia pachydermatis and Staphylococcus pseudintermedius in atopic dogs and their relationship with lesion scores.Vet Dermatol. 2020 Apr;31(2):111-115. doi: 10.1111/vde.12802. Epub 2019 Nov 6. Vet Dermatol. 2020. PMID: 31696563
-
Type-1 hypersensitivity reactions to Malassezia pachydermatis extracts in atopic dogs.Am J Vet Res. 1998 Jul;59(7):836-41. Am J Vet Res. 1998. PMID: 9659547
-
IgE sensitivity to Malassezia pachydermatis and mite allergens in dogs with atopic dermatitis.Vet Immunol Immunopathol. 2020 Aug;226:110070. doi: 10.1016/j.vetimm.2020.110070. Epub 2020 May 21. Vet Immunol Immunopathol. 2020. PMID: 32492589
-
An update on the treatment of canine atopic dermatitis.Vet J. 2016 Jan;207:29-37. doi: 10.1016/j.tvjl.2015.09.016. Epub 2015 Sep 16. Vet J. 2016. PMID: 26586215 Review.
-
The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneous infections to the pathogenesis and clinical course of canine atopic dermatitis.Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):239-49. doi: 10.1016/s0165-2427(01)00345-2. Vet Immunol Immunopathol. 2001. PMID: 11553386 Review.
Cited by
-
Immune Response of the Host and Vaccine Development.Pathogens. 2023 Apr 24;12(5):637. doi: 10.3390/pathogens12050637. Pathogens. 2023. PMID: 37242307 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous